Advances in biomarker testing, analytical methods, and real-world datasets (RWD) that include biomarker and clinical data are rapidly enhancing precision oncology, enabling both forward and reverse translation and allowing for more effective patient-specific treatments.
These innovations play a crucial role in drug development, as well as clinical, payor, and regulatory decision making. However, it’s crucial to consider the strengths and limitations of different approaches and datasets when designing analyses and interpreting precision oncology data.
In this on-demand webinar, sponsored by Flatiron Health, Milan Radovich, chief scientific officer at Caris Life Sciences, Charu Aggarwal, from the University of Pennsylvania, and Neal Meropol, vice president of research oncology at Flatiron Health, explore the evolving state of precision oncology research and the pivotal role that high-quality linked clinical and multiomic RWD plays in accelerating all stages of drug development to maximize the success of novel therapeutics.
The speakers discuss:
- The rapidly evolving state of precision oncology research.
- Key considerations for different methodological approaches and datasets when designing or interpreting data from precision oncology research.
- Case studies highlighting how RWD can be used more effectively in precision oncology research to drive the development of novel and effective therapies, guide clinical, payor, and regulatory decision-making, and improve patient outcomes.
Offered Free by: Flatiron Health
See All Resources from: Flatiron Health
